YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
Retrieved on:
Tuesday, May 7, 2024
University, Cancer, Zoom, Exchange Square, Infection, Mass meeting, Growth, YS, Vaccine, Oracle, TMT, Proxy, Council, EGM, Silicon, Eastern Time Zone, Connaught Place, Interim, MBA, Series, Health, Management
Holders of record of the Company's ordinary shares as of the record date shall be entitled to attend and vote at the EGM and any adjourned meeting thereof.
Key Points:
- Holders of record of the Company's ordinary shares as of the record date shall be entitled to attend and vote at the EGM and any adjourned meeting thereof.
- In addition, the board of directors of the Company (the "Board") has approved the appointment of Mr. Dave Chenn as the Interim Chief Executive Officer of the Company (the "Interim CEO"), as well as the appointment of Dr. Hui Shao, the then-current Chief Executive Officer of the Company, as the Co-Chief Executive Officer and Chief Business Officer of the Company, each effective on May 2, 2024.
- Mr. Chenn currently serves as Chief Executive Officer and Managing Partner of Oceanpine.
- The EGM Notice contains the details of the Zoom dial-in and instructions on how to vote for the EGM.